Advances in cancer immunotherapy under spotlight

Top cancer researchers and scientists are to attend the 28th annual scientific meeting and associated programmes to highlight cancer treatment next month.

The researchers and experts in the cancer immunotherapy field will present cutting-edge findings and define the state of the art field of cancer immunotherapy, which has developed significantly over the course of this year. The congress will be held from 7 November in National Harbor, just outside Washington.

Among the topics under discussion will be a workshop on personalised cancer immunotherapy; basic coverage on tumour immunology and cancer immunotherapy, as well as technological advances in genomics, proteomics and immunophenotyping and what this means for improving cancer patient outcomes.

A symposium on predictive biomarkers in PD-L1 tumours will also take place.

It will give scientists and researchers the opportunity to forge strategic partnerships as well as intimate channels of discussion on current clinical trials; methodologies  and new initiatives in tumour immunology and cancer immunotherapy between basic and clinical researchers, regulatory agencies and the biotech/pharmaceutical industry.
The Society for Immunotherapy of Cancer, founded in 1984, is a non-profit organisation of clinicians, researchers, students, post-doctoral fellows and allied health professionals dedicated to improving cancer patient outcomes by advancing the development and application of cancer immunotherapy through interaction.

More information available at

Photo about petri dish from Shutterstock

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Voting Booth
Have you entered our Health of the Nation survey?
Please select an option Oops! Something went wrong, please try again later.
29% - 9748 votes
71% - 23951 votes